Curative by Design™
An ideal target for solid tumors is a protein that is pivotal to the perpetuation of cancer and only found in cancer.
So how do we mine for these valuable protein gems: by digging deep into the connections between the biology of regeneration and cancer with the help of our SeleCTR™ process and algorithm.
We delve into the biology of cells and tissues undergoing development or renewal in search of regenerative nexuses.
A regenerative nexus represents a core aspect of tissue regeneration. Nexuses must work in concert to maintain a capacity for regeneration, and, in the case of cancer, its ability to persist and return.
A cancer-specific protein change that governs a nexus, creates a High Curative Potential™ (HCP) Target.
The nature of an HCP Protein Target means it is likely to be retained as the cancer advances and is also likely to be shared between cancer patients. This creates the possibility of serving a broad population of patients with a reliably potent T cell therapy.
Independent clinical studies have reported the retention of shared HCP target gene expression in patients with metastatic disease.
Learn how we'll get from targets to therapies.